• Revenue up 16.5% to $11.34 million
• Profit before tax of $0.04 million (vs loss of $1.98 million in PCP)
• EBITDA of $0.8 million reflecting improved margins and operating leverage
• Two consecutive quarters of positive operating cash flow

ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis company, has released its Half Year Financial Report for the six months ended 31 December 2025 (H1 FY26), marking a clear inflection point for the company. The key highlights include: revenue of $11.34 million, up 16.5% on the prior corresponding period (PCP); profit before tax of $0.04 million (PCP: loss of $1.98 million); EBITDA of $0.8 million reflecting improved margins and operating leverage; and two consecutive quarters of positive operating cash flow, a significant turnaround from the prior year. The strategic shift towards branded products, with the branded direct-to-consumer (B2C) portfolio now accounting for approximately 60% of total revenue, has been a key driver of the improved financial performance. The company has also completed major infrastructure expansion, enabling 12-month production capacity, and strengthened its balance sheet through a $1.95 million capital raising. ECS enters the second half of FY26 with improved financial resilience and a clear pathway to disciplined, sustainable growth.

The company has not provided any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics.

ECS enters the second half of FY26 with improved financial resilience and a clear pathway to disciplined, sustainable growth, building on the progress made in the first half of the year.